Trum 3

Ceftazidime Pentahydrate USP

Composition : Ceftazidime USP 250mg, 500mg & 1gm Injection.

Indication : It is indicated for the treatment of single infections and for mixed infections caused by susceptible organisms. S evere infections in general : for example septicaemia, bacteraemia, peritonitis, meningitis, infections in immunosuppressed patients and in patients in intensive care units with specific problems. R espiratory tract infections : for example, pneumonia, bronchopneumonia, infected pleuris y, empyema, lung abs cess, infected bronchiectasis, bronchitis and lung infections in patients with cystic fibrosis. E ar, nose and throat infections : otitis media, otitis externa, mastoiditis, sinusitis and other severe ear and throat infections. Urinary tract infections: acute and chronic pyelonephritis, pyelitis, prostatitis, cystitis, urethritis, renal abscess. S kin and soft tissue infections: abscess, cellulitis, infected burn and wounds, skin ulcers etc. Gastrointestinal biliary and abdominal infections : cholangitis, cholecystitis, intraabdominal abscess, peritonitis etc. Bone and joint infections : Osteomyelitis, septic arthritis etc.

Dosage and administration :Adults : The adult dosage range for Ceftazidime is 1gm to 6gm per day 8 or 12 hourly (IM or IV). In the majority of infections, 1gm 8 hourly or 2gm 12 hourly should be given. In urinary tract infections and many less serious infections, 250mg or 500mg or 1gm 12 hourly is usually adequate. In very severe infections, especially immunocompromis ed patients, including those with neutropenia, 2gm 8 or 12 hourly or 3gm 12 hourly should be administered or as directed by the registered physician. Infants and children : The usual dosage range for children aged over 2 months is 30 to 100mg/kg/day, given as two or three divided doses.

Use in pregnancy and lactation : Ceftazidime has been assigned to pregnancy category B by the FDA.

Packing : 1 Combipack.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.